European Biotech Acquisition Stock Fundamentals

EBACDelisted Stock  USD 11.19  0.10  0.90%   
European Biotech Acquisition fundamentals help investors to digest information that contributes to European Biotech's financial success or failures. It also enables traders to predict the movement of European Stock. The fundamental analysis module provides a way to measure European Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to European Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

European Cash And Equivalents Analysis

European Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

 = 

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current European Biotech Cash And Equivalents

    
  308.1 K  
Most of European Biotech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, European Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition

In accordance with the recently published financial statements, European Biotech Acquisition has 308.1 K in Cash And Equivalents. This is 100.0% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The cash and equivalents for all United States stocks is 99.99% higher than that of the company.

European Biotech Acq Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining European Biotech's current stock value. Our valuation model uses many indicators to compare European Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across European Biotech competition to find correlations between indicators driving European Biotech's intrinsic value. More Info.
European Biotech Acquisition is one of the top stocks in book value per share category among related companies. It is one of the top stocks in total asset category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value European Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for European Biotech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the European Biotech's earnings, one of the primary drivers of an investment's value.

European EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses European Biotech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of European Biotech could also be used in its relative valuation, which is a method of valuing European Biotech by comparing valuation metrics of similar companies.
European Biotech is currently under evaluation in ebitda category among related companies.

European Fundamentals

About European Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze European Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of European Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of European Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
European Biotech Acquisition Corp. does not have significant operations. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands. European Biotech is traded on NASDAQ Exchange in the United States.

Pair Trading with European Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if European Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in European Biotech will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to European Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace European Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back European Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling European Biotech Acquisition to buy it.
The correlation of European Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as European Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if European Biotech Acq moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for European Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the European Biotech Acq information on this page should be used as a complementary analysis to other European Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in European Stock

If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device